Horwell, David Christopher,Scopes, David Ian Carter
申请号：
AU2011254669
公开号：
AU2011254669A1
申请日:
2011.05.16
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof wherein X is N or CH； Q is NR or O； A and A are independently hydrogen or C alkyl or may together form a carbonyl group； R and R are independently hydrogen, halogen, CF, CN, OR, OR, NRR, NRCOR, NRS0R, S0NRR, SOR or C alkyl optionally and independently substituted by one or more of hydroxyl, C alkoxy, halogen or NR R； R 3 is hydrogen, halogen, CF3 or OR 7； R4 is hydrogen, halogen, CF3, OR8, NR8R9, NR8COR10, NR8S02R10 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR 8 R 9； or when R and R are positioned ortho and taken together form -0(CH)O-, where m is 1-3； R is hydrogen or C alkyl optionally substituted by hydroxyl, C alkoxy or NR R； R is hydrogen or C alkyl； R is hydrogen or C alkyl optionally substituted by OR or NRR； R is hydrogen, C alkyl, optionally substituted by hydroxyl or C alkoxy or C alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C alkyl, CF, OR, NRR or OCF； or the groups R and R when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR, S and O said 5 or 6 membered ring being optionally substituted by hydroxyl or C alkoxy； or the groups R and R when they are attached to a nitrogen atom may together form an azetidinyl ring optionally substituted by hydroxyl or C alkoxy； and R is C alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C alkyl, CF, OCF or OR； and n is 1 or 2. The use of the compounds in treating amyloid disease is also disclosed.
